AdvertisementControversy Continues Over Muscular Dystrophy Drug, Despite FDA ApprovalSeptember 24, 2016Richard HarrisfacebookEmailDuchenne muscular dystrophy patients Jack Willis (center), Nolan Willis (right) and Max LeClaire, attended the opening of Sarepta Therapeutics new headquarters in Cambridge, Mass., in 2014. (Boston Globe via Getty Images)
